SCHEMBL4201829

SCHEMBL4201829

CSc1ccc(-c2sc(NC(C)=O)nc2C)cn1

nearest known ligand 0.61

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
PIK3CG P48736 15/20 0.61
PIK3CA P42336 11/20 0.61
PIK3CB P42338 11/20 0.61
PIK3CD O00329 11/20 0.61
PI4KB Q9UBF8 4/20 0.49
PIK3C2A O00443 2/20 0.49
PIK3C2B O00750 2/20 0.49
STK17A Q9UEE5 2/20 0.49
RPS6KA4 O75676 1/20 0.49
CYP3A4 P08684 1/20 0.49
DYRK3 O43781 1/20 0.48
MAP4K4 O95819 1/20 0.48
CDK9 P50750 1/20 0.48
MAP4K2 Q12851 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL925027 0.82 PIK3CG (0.64) PIK3CGPIK3CAPIK3CBPIK3CDPI4KB
SCHEMBL924622 0.82 PIK3CG (0.64) PIK3CGPIK3CAPIK3CBPIK3CDPI4KB
SCHEMBL923907 0.80 PIK3CG (0.63) PIK3CGPIK3CAPIK3CBPIK3CDPI4KB
SCHEMBL13948300 0.79 PIK3CG (0.70) PIK3CGPIK3CAPIK3CBPIK3CDPI4KB
SCHEMBL4209112 0.79 PIK3CG (0.62) PIK3CGPIK3CAPIK3CBPIK3CDPI4KB
SCHEMBL924832 0.78 PIK3CG (0.60) PIK3CGPIK3CAPIK3CBPIK3CDPI4KB
SCHEMBL48461 0.77 PIK3CG (0.76) PIK3CGPIK3CAPIK3CBPIK3CD
Trifluoroacetic Acid SCHEMBL924839 0.76 PIK3CG (0.56) PIK3CGPIK3CAPIK3CBPIK3CDPI4KB
SCHEMBL4204664 0.76 PIK3CG (0.55) PIK3CGPIK3CAPIK3CBPIK3CDPI4KB
SCHEMBL48393 0.76 PIK3CG (0.74) PIK3CGPIK3CAPIK3CBPIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090029997-A1 Thiazole Derivatives and Use Thereof LABORATOIRES SERONO SA (CH) 2009-01-29 US claimed
EP-1979346-A1 THIAZOLE DERIVATIVES AND USE THEREOF LABORATOIRES SERONO S.A. (CH) 2008-10-15 EP claimed
WO-2007082956-A1 THIAZOLE DERIVATIVES AND USE THEREOF LABORATOIRES SERONO S.A. (CH) 2007-07-26 WO claimed
US-20090029997-A1 Thiazole Derivatives and Use Thereof LABORATOIRES SERONO SA (CH) 2009-01-29 US disclosed
EP-1979346-A1 THIAZOLE DERIVATIVES AND USE THEREOF LABORATOIRES SERONO S.A. (CH) 2008-10-15 EP disclosed
WO-2007082956-A1 THIAZOLE DERIVATIVES AND USE THEREOF LABORATOIRES SERONO S.A. (CH) 2007-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090029997-A1 Thiazole Derivatives and Use Thereof PDGFRB, PDGFRA, TEC PIK3CG 2526/4885PIK3CA 1647/4885PIK3CB 1861/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.